Bayer: Neoplasms trials

The registry lists 82 Neoplasms studies with Bayer as lead sponsor. 2 are open to participants now and 15 have results posted.

Phase 1 56Phase 2 12Phase 3 8Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 MutationAvailableNCT06761976
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid TumorsRecruitingNCT05954312Phase 1
• Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic CancerTerminatedNCT02168777Phase 1Results posted
• Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)CompletedNCT01976741Phase 1Results posted
• Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal ImpairmentCompletedNCT01853046Phase 1Results posted
• Continuous Dosing of BAY73-4506 in Patients With Advanced MalignanciesCompletedNCT01117623Phase 1Results posted
• Sorafenib Long Term Extension ProgramCompletedNCT00625378Phase 3Results posted
• Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)CompletedNCT00494299Phase 3Results posted
• A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00449033Phase 3Results posted
• BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell CarcinomaCompletedNCT00117637Phase 2Results posted
• Treatment for Subjects With Unresectable Stage III or Stage IV MelanomaCompletedNCT00110994Phase 2Results posted
• A Research Study to Treat Patients With Advanced Hepatocellular CarcinomaCompletedNCT00108953Phase 2Results posted
• A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT00105443Phase 3Results posted
• BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)CompletedNCT00101413Phase 2Results posted
• BAY43-9006 - Phase II in Advanced Breast CancerCompletedNCT00101400Phase 2Results posted
• Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell CancerCompletedNCT00073307Phase 3Results posted
• A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular CarcinomaCompletedNCT00044512Phase 2Results posted
• Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their DoctorsNo longer availableNCT06238583
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic TumorsTerminatedNCT06188208Phase 1
• An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)CompletedNCT05461807
• Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by BayerActive, not recruitingNCT04464226Phase 3
• Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its SafetyCompletedNCT04125693Phase 2
• Rogaratinib (BAY1163877) in Chinese PatientsCompletedNCT03788603Phase 1
• Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid TumorsCompletedNCT03102320Phase 1
• Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid TumorsCompletedNCT02746081Phase 1
• A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active CancerCompletedNCT02742623
• Phase I Study of Anetumab Ravtansine in Hepatic or Renal ImpairmentCompletedNCT02696642Phase 1
• A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenActive, not recruitingNCT02637687Phase 1/2
• Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid TumorsCompletedNCT02592785Phase 1
• A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsCompletedNCT02576431Phase 2
• Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced MalignanciesCompletedNCT02485119Phase 1
• Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone LesionsCompletedNCT02442063Phase 1
• Regorafenib Phase I Study in Mainland Chinese PatientsCompletedNCT02398513Phase 1
• Roniciclib Mass Balance StudyCompletedNCT02390154Phase 1
• BAY1238097, First in ManTerminatedNCT02369029Phase 1
• Phase I Study of Oral BAY 1217389 in Combination With Intravenous PaclitaxelCompletedNCT02366949Phase 1
• A Drug Utilization Study of Radium-223 in SwedenCompletedNCT02331303
• Dose-escalation Study of Lupartumab Amadotin (BAY1129980)TerminatedNCT02134197Phase 1
• Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.CompletedNCT02106845Phase 1
• A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard TherapyCompletedNCT02085148Phase 1
• Japanese BAY1000394 Monotherapy Phase I StudyCompletedNCT02047890Phase 1
• Safety and Effectiveness of RegorafenibCompletedNCT02042144
• Effect of Neomycin on the Pharmacokinetics of RegorafenibCompletedNCT02001909Phase 1
• Safety and Pharmacokinetics of Regorafenib and Cetuximab in CombinationCompletedNCT01973868Phase 1
• Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced CancerCompletedNCT01938638Phase 1
• Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in PatientsCompletedNCT01915576Phase 1
• First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid TumorsCompletedNCT01881217Phase 1
• BAY86-9766 Plus Gemcitabine Phase I Study in AsianCompletedNCT01764828Phase 1
• Open Label Study of BAY1082439 in Patients With Advanced CancerCompletedNCT01728311Phase 1
• Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in CombinationCompletedNCT01585870Phase 1
• Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced CancerCompletedNCT01460537Phase 1
• Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.CompletedNCT01439152Phase 1
• Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced CancerCompletedNCT01411410Phase 1
• Japanese BAY80-6946 Monotherapy Phase I StudyCompletedNCT01404390Phase 1
• Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced CancerCompletedNCT01392521Phase 1
• Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor ActivityCompletedNCT01339104Phase 1
• Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced MalignanciesCompletedNCT01335256Phase 1
• Effect of Rifampin on the Pharmacokinetics of BAY73-4506CompletedNCT01322438Phase 1
• Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced MalignanciesTerminatedNCT01297530Phase 1
• BAY73-4506 Probe Substrate StudyCompletedNCT01287598Phase 1
• Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced MalignanciesCompletedNCT01188252Phase 1
• Japanese BAY86-9766 Monotherapy Phase I StudyCompletedNCT01179295Phase 1
• Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid TumorsCompletedNCT01096030Phase 1
• Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)CompletedNCT01069328Phase 1
• Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid TumorsTerminatedNCT01065623Phase 1
• Gadobutrol Magnevist-controlled Body StudyCompletedNCT01050829Phase 3
• To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid TumorsCompletedNCT01028755Phase 1
• Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy VolunteersTerminatedNCT00975299Phase 1
• BAY80-6946 Open Label, Phase I Study in Patients With Advanced CancerCompletedNCT00962611Phase 1
• Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY 85-8050 in Healthy Volunteers and PatientsCompletedNCT00961831Phase 1
• Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.CompletedNCT00960258Phase 1
• Extension Program for Bay 43-9006CompletedNCT00657254Phase 2
• Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid TumorsCompletedNCT00606125Phase 1
• Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and DoxorubicinCompletedNCT00562913Phase 1
• Sorafenib/Docetaxel Dose Escalation TrialCompletedNCT00562523Phase 1
• An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell CarcinomaCompletedNCT00492986Phase 3
• Investigation of Mass Balance of the Test Drug and Major MetabolitesCompletedNCT00432302Phase 1
• Dose Escalation Study of SH U04722 in Solid TumorsTerminatedNCT00375453Phase 1
• Phase IV Randomization to On-Going Treatment to Evaluate Sustained SorafenibTerminatedNCT00352859Phase 4
• Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer PatientsCompletedNCT00259129Phase 1
• Research Study for Patients With Metastatic Renal Cell CarcinomaTerminatedNCT00110344Phase 2
• Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory CancerCompletedNCT00079612Phase 2